Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2025-06-30 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : Le riliprubart obtient la désignation de médicament orphelin au Japon pour la polyneuropathie inflammatoire démyélinisante chronique
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing that their drug candidate, riliprubart, has received orphan drug designation in Japan for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). It provides details on the drug's clinical development, the nature of the disease, and includes standard corporate boilerplate, contact information, and forward-looking statements. As this is a general regulatory/corporate announcement that does not fit into specific categories like financial reports, earnings releases, or governance filings, it is classified as a Regulatory Filing (RNS).
2025-06-30 French
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi announcing that their drug candidate, riliprubart, has been granted orphan drug designation by the Japanese Ministry of Health, Labour and Welfare. It provides details on the drug's clinical development status, the condition it treats (CIDP), and includes standard corporate boilerplate, media/investor contact information, and forward-looking statements. As this is a general corporate announcement regarding regulatory milestones and product development that does not fit into specific financial reporting categories like 10-K, IR, or ER, it is classified as a Regulatory Filing (RNS).
2025-06-30 English
FORM 11-K
Regulatory Filings
2025-06-27 English
FORM 11-K
Regulatory Filings
2025-06-27 English
Communiqué de presse : Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing that the FDA has granted orphan drug designation to their experimental drug 'riliprubart'. It details the clinical development status, the medical condition it targets, and includes standard corporate boilerplate, contact information, and forward-looking statements. As it is a general regulatory/corporate announcement that does not fit into specific categories like financial reports, earnings releases, or shareholder meeting materials, it is classified as a general regulatory filing.
2025-06-25 French
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi regarding a regulatory milestone (FDA orphan drug designation) for a clinical-stage drug candidate (riliprubart). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate announcement regarding clinical development and regulatory status, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback.
2025-06-25 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.